Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
about
Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cellsMicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1Silent Polymorphisms: Can the tRNA Population Explain Changes in Protein Properties?Alternative splicing for diseases, cancers, drugs, and databasesNeuroprotective effects of estrogens and androgens in CNS inflammation and neurodegenerationThe substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells.Pathways to tamoxifen resistance.The color appearance of stimuli detected via short-wavelength-sensitive cones: comparisons with visual adaptation and visual field data for peri- or post-menopausal women under 70 years of age.Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice.Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanismER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerMechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytesTranscription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.Genotoxicity of the some selective estrogen receptor modulators: a reviewEstrogens and the pathophysiology of the biliary treePartial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsivenessA noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.Genetic rescue of nonclassical ERα signaling normalizes energy balance in obese Erα-null mutant mice.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Interaction of diuron and related substituted phenylureas with the Ah receptor pathway.Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor.Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sitesAn anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cellsEffects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Designing the ideal selective estrogen receptor modulator--an achievable goal?HEXIM1 is a critical determinant of the response to tamoxifen.Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.Aryl hydrocarbon receptor ligands in cancer: friend and foe.Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugsExpression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.Aromatase inhibitors: a safety comparison.SUMO and estrogen receptors in breast cancer.Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.Antiestrogens and the formation of DNA damage in rats: a comparison.Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis
P2860
Q24293644-92B0D069-B534-48C8-A47E-F946A0DC516DQ24648241-0E2FCC62-7F59-4596-BBEC-471AA047ADC5Q26768439-EA9C81BB-8A92-438F-A87F-AEEA9778A0F1Q26852848-886B1042-6DF5-4C2B-8650-3111BD6E707DQ27023974-742FC35F-311E-4138-A6D1-354FA0F458F8Q30157272-C42B2BDF-DDAC-47DA-BA60-93D3A26557C5Q30441001-B59D42C8-6337-4115-8F4D-7B093E28E051Q31149665-D5A41BD9-1160-4DC6-A85D-8AC7B3F1CC68Q33287050-D3B6156E-6486-4815-BF29-BBE7F220C425Q33432584-5D1A3E82-FE82-4F1B-A647-FB629B4E9AB8Q33528959-1C040325-409A-4EB7-9175-0EE059FC1525Q33611502-8D55DE0B-C110-42DD-AEAD-CB85B8EAC310Q33769843-3D50C230-E9C0-4603-88C7-E945EB6141D5Q33820278-7CB470BF-9012-4C11-B320-850771FAF394Q33849496-7E3D46E3-D71B-4335-A189-0D3BCE4D3236Q33866800-5D419ADE-12AF-43BF-9782-7CF45C85FD58Q34038020-8CA567F0-6EA1-42D1-A057-6309ACA4C340Q34438994-14712458-625C-4649-AB19-0AD08F823F52Q34452797-374FF243-F57E-46F7-B87D-BA8861E0C90CQ34519812-D3119A8D-D0C9-4A58-BEAA-A933515685BDQ34534031-ED04A238-C2B2-4632-9A62-2A0AADF8BF4BQ34544390-D3D75AF2-6B1A-4452-9306-D72711693193Q34563775-6962D0E8-9EAD-4339-8201-AB059BF88F72Q34682354-BF8CE130-C739-4365-98A6-2F9DEE854FAFQ34765600-7D05BC89-7452-4517-9FAF-390BAC205B18Q34908885-9E326089-1F97-480C-BC03-DF7EA31218F5Q35023776-A39F961F-C2C0-4780-9148-C7DBC016244DQ35106333-2B10CECC-E843-45D7-BAAF-8817F83A8BEFQ35233145-81308CD9-AD2D-43AA-A8B2-8EFFF5372EBCQ35458027-D3EB079C-C186-4762-ACD7-D88D86C7B9B1Q35889618-380D2B1B-9775-41C7-B52E-2A022BC85293Q35992843-C988DBFF-0C83-46A1-9D96-A65DA3BC6581Q36023355-0ABC5B13-0CF2-41D2-A82C-6642F498164EQ36078905-41AB50D7-F431-4560-9924-FBDBEE28170BQ36741592-2A60106C-F20E-467C-AEC3-810F6228A4C5Q36762444-E207E3E7-02E7-40AB-9BD5-CC23998DE4AEQ36766502-E92B5E07-DF75-473F-AC35-B294547405F3Q36849529-BBC6377A-8D72-41D5-9340-6F7C35C72A0DQ36871805-FD741BE6-68DA-4097-8762-9750ACDF4096Q36874786-ACCEAD74-93E7-4B20-8552-29200B3CA3F2
P2860
Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@ast
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@en
type
label
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@ast
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@en
prefLabel
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@ast
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@en
P1433
P1476
Selective estrogen receptor mo ...... nogenesis and drug resistance.
@en
P2093
Joan S Lewis
V Craig Jordan
P304
P356
10.1016/J.MRFMMM.2005.02.028
P407
P577
2005-08-03T00:00:00Z